Discovery of a Potent RXRγ Degrader WCF-598 for the Treatment of Castration-Resistant Prostate Cancer - PubMed
4 hours ago
- #Prostate Cancer
- #RXRγ Degrader
- #PROTAC
- Castration-resistant prostate cancer (CRPC) lacks effective treatments, making RXRγ a new target.
- WCF-598 is a potent RXRγ degrader developed using the PROTAC approach, showing specificity over RXRα and RXRβ.
- WCF-598 induces tumor regression in CRPC models without toxicity and also degrades AR-V7, a resistance driver.
- The study positions WCF-598 as a tool for exploring RXRγ's role in CRPC and related diseases.